EXHIBIT 10.54 BNP AGREEMENT (1995) entered into as of November 17, 1995 by and between SCIOS NOVA INC. 2450 Bayshore Parkway Mountain View, CA 94043/USA (hereinafter referred to as "SCIOS NOVA") and BIOCHEMIE GESELLSCHAFT M.B.H. A-6250 Kundl/Austria...Confidential Treatment Requested • August 14th, 2002 • Scios Inc • Pharmaceutical preparations
Confidential Treatment Requested. Confidential portions of this document have been redacted and have been separately filed with the Commission. BLACKHAWK BIOFUELS, LLC TOLL PROCESSING AGREEMENTConfidential Treatment Requested • January 19th, 2010 • Blackhawk Biofuels, LLC • Industrial organic chemicals • Iowa
This Blackhawk Biofuels, LLC Toll Processing Agreement (the “Agreement”) is made and entered into effective January 1, 2010, by and between Blackhawk Biofuels, LLC a limited liability company organized and existing under the laws of the state of Delaware, with offices at 22 South Chicago Avenue, Freeport, Illinois 61032 (“Blackhawk Biofuels”). and REG Marketing & Logistics Group, LLC, an Iowa limited liability company (“REG Marketing”), of 416 S. Bell Avenue, PO Box 888, Ames, Iowa 50010 (each a “Party,” and collectively the “Parties”).
LICENSE AND COLLABORATION AGREEMENT BY AND BETWEEN TAKEDA PHARMACEUTICAL COMPANY LIMITED AND ULTRAGENYX PHARMACEUTICAL INC. JUNE 6, 2016Confidential Treatment Requested • December 12th, 2016 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations • New York
This License and Collaboration Agreement (this “Agreement”) is made as of the 6th day of June, 2016 (the “Execution Date”) by and between Takeda Pharmaceutical Company Limited, a company incorporated under the laws of Japan having its principal place of business at 1-1, Doshomachi 4-chome, Chuo-ku, Osaka 540-8645, Japan (“Takeda”), and Ultragenyx Pharmaceutical Inc., a company incorporated under the laws of California, having its principal place of business at 60 Leveroni Court, Novato, CA 94949, United States (“Ultragenyx”). Ultragenyx and Takeda are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
Confidential Treatment Requested Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. WEBBANK and LENDINGCLUB CORPORATION SECOND AMENDED AND RESTATED LOAN ACCOUNT PROGRAM...Confidential Treatment Requested • December 4th, 2014 • LendingClub Corp • Finance services • Utah
This SECOND AMENDED AND RESTATED LOAN ACCOUNT PROGRAM AGREEMENT (this “Agreement”), dated as of February 28, 2014 (“Effective Date”), is made by and between WEBBANK, a Utah-chartered industrial bank having its principal location in Salt Lake City, Utah (“Bank”), and LENDINGCLUB CORPORATION, a Delaware corporation, having its principal location in San Francisco, California (“Company”).
Confidential Treatment Requested Confidential portions of this document have been redacted and have been separately filed with the Commission RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT between Vertex Pharmaceuticals Incorporated and Cystic...Confidential Treatment Requested • August 19th, 2011 • Vertex Pharmaceuticals Inc / Ma • Pharmaceutical preparations • Massachusetts
This Agreement is a modification and continuation of a relationship originally set forth in an earlier Cystic Fibrosis Research Alliance and Commercialization Agreement dated as of May 19, 2000 (the “Original Agreement”), between the Cystic Fibrosis Foundation, which is an Affiliate of CFFT, and Aurora Biosciences Corporation, which was acquired by Vertex in 2001. Except as specifically provided herein, this Agreement supercedes in its entirety the Original Agreement which shall be of no further force and effect.
CONFIDENTIAL TREATMENT REQUESTEDConfidential Treatment Requested • July 31st, 2018 • Pieris Pharmaceuticals, Inc. • Services-commercial physical & biological research • New York
This License and Collaboration Agreement is entered into as of February 8, 2018 (the “Effective Date”) by and among Seattle Genetics, Inc., a Delaware corporation located at 21823 30th Drive SE, Bothell, WA 98021 (together with its Affiliates, “SGEN”), and Pieris Pharmaceuticals, Inc., a Nevada corporation located at 255 State Street, 9th floor, Boston, MA 02109 and Pieris Pharmaceuticals GmbH, a company organized and existing under the laws of Germany located at Lise-Meitner-str. 30, 85354 Freising, Germany (collectively and together with their Affiliates, “PIRS”). SGEN and PIRS are individually referred to herein as a “Party” and collectively, as the “Parties”.
CONFIDENTIAL TREATMENT REQUESTED WEBBANK and PROSPER MARKETPLACE, INC. STAND BY LOAN PURCHASE AGREEMENT Dated as of January 25, 2013Confidential Treatment Requested • January 28th, 2013 • Prosper Funding LLC • Finance services • Utah
This STAND BY LOAN PURCHASE AGREEMENT (this “Agreement”), dated as of January 25, 2013 (“Effective Date”), is made by and between WEBBANK, a Utah-chartered industrial bank having its principal location in Salt Lake City, Utah (“Bank”), and PROSPER MARKETPLACE, INC., a Delaware corporation, having its principal location in San Francisco, California (“PMI”).
Amendment 5 To the Distributor Agreement between Avnet, Inc. and Aruba Networks, Inc.Confidential Treatment Requested • September 24th, 2014 • Aruba Networks, Inc. • Computer peripheral equipment, nec
This Amendment 5 (“Amendment) is effective February 1, 2013 (“Effective Date”), to the Distributor Agreement (the “Agreement”) effective June 15, 2007, between Aruba Networks, Inc. (“Aruba”) and Avnet, Inc. (“Avnet”).
SUPPLEMENTAL AGREEMENTConfidential Treatment Requested • April 29th, 2011 • Boingo Wireless Inc • Communications services, nec
THIS AGREEMENT, made as of March 28, 2001 by and between THE PORT AUTHORITY OF NEW YORK AND NEW JERSEY (hereinafter called the “Port Authority”) and NEW YORK TELECOM PARTNERS, LLC (hereinafter called the “Permittee”),
CONFIDENTIAL TREATMENT REQUESTED AMENDMENT AGREEMENT NO. 2 TO THE RESEARCH COLLABORATION AND LICENSE AGREEMENTConfidential Treatment Requested • August 12th, 2014 • Vitae Pharmaceuticals, Inc • Pharmaceutical preparations
This Amendment Agreement No. 2 (“Amendment”) is made to the BACE Research Collaboration and License Agreement between Vitae Pharmaceuticals, Inc. (“Vitae”), with offices at 502 West Office Center Drive, Fort Washington, PA 19034, USA (taxpayer ID number 04-03567753), and Boehringer Ingelheim International GmbH (“BI”), with offices at **** (VAT ID number ****), effective as of June 4, 2009, as amended in the Amendment No. 1 dated June 7, 2011 (together the “Agreement”).
FIRST AMENDMENT TO DATAFEED LICENSE AGREEMENTConfidential Treatment Requested • July 2nd, 2010 • MSCI Inc. • Services-business services, nec
This First Amendment to Datafeed License Agreement (“Amendment”) is effective as of the 3rd day of January, 2005 (“Effective Date”), by and between ADP Investor Communication Services, Inc., a Delaware corporation (“ADP”), and Institutional Shareholder Services Inc. ( “ISS”), a Delaware corporation (each a “party” and collectively the “parties”).
CONFIDENTIAL TREATMENT REQUESTED STOCK PURCHASE AGREEMENT among SPERO CANTAB, INC., SPERO CANTAB UK LIMITED, SPERO THERAPEUTICS, LLC, PBB DISTRIBUTIONS LIMITED, NEW PHARMA LICENSE HOLDINGS LIMITED, CANTAB ANTI-INFECTIVES LTD, and PRO BONO BIO PLC...Confidential Treatment Requested • September 29th, 2017 • Spero Therapeutics, Inc. • Pharmaceutical preparations • England and Wales
Each of the Milestone Payments shall be payable a maximum of one (1) time only even if achieved more than one (1) time with one or more Products. For the avoidance of doubt, (x) each of the Milestone Payments shall become payable upon the occurrence of the associated Milestone Event, irrespective of the order in which the Milestone Events occur relative to each other, and (y) no amounts shall be due for subsequent or repeated achievements of any Milestone Event.
CONFIDENTIAL TREATMENT REQUESTED Amendment No. 1Confidential Treatment Requested • August 12th, 2014 • Vitae Pharmaceuticals, Inc • Pharmaceutical preparations
This Amendment No. 1 to the Agreement sets forth the mutual understanding concerning modifications of this Agreement. Capitalized terms used in this 1st Amendment and not otherwise defined shall have the same meanings herein as assigned to such terms in the Agreement. For good and valuable consideration, the adequacy of which is hereby acknowledged, the Parties agree as follows:
CONFIDENTIAL TREATMENT REQUESTED AMENDMENT AGREEMENT NO. 3 TO THE RESEARCH COLLABORATION AND LICENSE AGREEMENTConfidential Treatment Requested • August 12th, 2014 • Vitae Pharmaceuticals, Inc • Pharmaceutical preparations
This Amendment Agreement No. 3 (“Amendment”) is made to the Research Collaboration and License Agreement between Vitae Pharmaceuticals, Inc. (“Vitae”), with offices at 502
Confidential Treatment Requested. Confidential portions of this documents have been redacted and separately filed with the Commission. ***** Confidential material redacted and filed separately with the Commission.Confidential Treatment Requested • August 23rd, 2005 • XTL Biopharmaceuticals LTD • Pharmaceutical preparations
We set out below the amendments to the Agreement (as already amended by Amendment No. 1) and to Amendment No. 1 agreed between Yeda Research and Development Co. Ltd. (“Yeda”) and XTL Biopharmaceuticals, Ltd. (“the Corporation”) following discussions between the parties conducted at the Corporation’s request:
CONFIDENTIAL TREATMENT REQUESTED Option AgreementConfidential Treatment Requested • August 19th, 2008 • Alimera Sciences Inc • Pharmaceutical preparations • Georgia
This Option Agreement (the “AGREEMENT”) is made and entered into by and between EMORY UNIVERSITY, a nonprofit Georgia corporation with offices located at 1599 Clifton Road, 4th Floor, Atlanta, Georgia 30322 (hereinafter referred to as “EMORY”) and Alimera Sciences, Inc., a Delaware corporation having a principal place of business located at 6120 Windward Parkway, Suite 290, Alpharetta, Georgia 30024 (hereinafter referred to as “COMPANY”).
CONFIDENTIAL TREATMENT REQUESTED EXCLUSIVE LICENSE AGREEMENTConfidential Treatment Requested • April 13th, 2017 • G1 Therapeutics, Inc. • Pharmaceutical preparations • Illinois
This Exclusive License Agreement (this “Agreement”), effective as of November 23, 2016 (“Effective Date”) between The Board Of Trustees Of The University Of Illinois, a body corporate and politic of the State of Illinois, 352 Henry Administration Building, 506 S. Wright St., Urbana, Illinois 61801 (“University”) and G1 Therapeutics, Inc. having a principal address at 79 T.W. Alexander Drive, 4401 Research Commons, Suite 105, Research Triangle Park, NC 27709 (“Licensee”).
CONFIDENTIAL TREATMENT REQUESTED: INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND NOTED WTH “**”. AN UNREDACTED VERSION OF THIS DOCUMENT HAS ALSO BEEN PROVIDED TO THE SECURITIES AND EXCHANGE COMMISSION. Dated 28 April...Confidential Treatment Requested • June 7th, 2004 • Genworth Financial Inc • Life insurance
CONFIDENTIAL TREATMENT REQUESTED DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENTConfidential Treatment Requested • August 12th, 2015 • Mabvax Therapeutics Holdings, Inc. • Pharmaceutical preparations • New York
This DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT, effective as of this 15th day of April 2014 (the “Effective Date”), between, MabVax Therapeutics, a Delaware Corporation (“Customer”), having its principal place of business at 11588 Sorrento Valley Road, Suite 20, San Diego CA 92121, and Gallus Biopharmaceuticals NJ, LLC, a Delaware limited liability company with offices at 201 College Road East, Princeton, NJ 08540 (“Gallus”). Customer and Gallus are referred to herein each as a “Party” and collectively as the “Parties”.
CONFIDENTIAL TREATMENT REQUESTED LICENSE AND OPTION AGREEMENT between EMORY UNIVERSITY and ALIMERA SCIENCES, INC.Confidential Treatment Requested • April 16th, 2010 • Alimera Sciences Inc • Pharmaceutical preparations • Georgia
THIS LICENSE AND OPTION AGREEMENT is made and entered into as of the 16th day of July, 2009, (hereinafter referred to as the “Effective Date”) by and between EMORY UNIVERSITY, a nonprofit Georgia corporation with offices located at 1599 Clifton Road NE, 4th Floor, Atlanta, Georgia 30322 (hereinafter referred to as “EMORY”) and Alimera Sciences, Inc., a Delaware corporation having a principal place of business located at 6120 Windward Parkway, Suite 290, Alpharetta, Georgia 30024 (hereinafter referred to as “ALIMERA”).
Confidential Treatment Requested. Confidential portions of this document have been redacted and separately filed with the Commission. ***** Confidential material redacted and filed separately with the Commission LICENSE AGREEMENTConfidential Treatment Requested • August 23rd, 2005 • XTL Biopharmaceuticals LTD • Pharmaceutical preparations • California
Effective as of September 12, 2003 ("Effective Date"), THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, a body having corporate powers under the laws of the State of California ("STANFORD"), and XTL Biopharmaceuticals Ltd., a corporation organized under the laws of Israel having a principal place of business at Kiryat Weizmann, P.O. Box 370, Rehovot, 76100 Israel ("LICENSEE"), agree as follows:
CONFIDENTIAL TREATMENT REQUESTED AMENDMENT AGREEMENT NO. 3 TO THE RESEARCH COLLABORATION AND LICENSE AGREEMENTConfidential Treatment Requested • August 12th, 2014 • Vitae Pharmaceuticals, Inc • Pharmaceutical preparations
This Amendment Agreement No. 3 (“Amendment 3”) is made to the BACE Research Collaboration and License Agreement between Vitae Pharmaceuticals, Inc. (“Vitae”), with offices at 502 West Office Center Drive, Fort Washington, PA 19034, USA (taxpayer ID number 04-03567753), and Boehringer Ingelheim International GmbH (“BI”), with offices at ****(VAT ID number ****), effective as of June 4, 2009, as last amended by the Amendment No. 2 (“Amendment 2”) dated December 21, 2012 (together the “Agreement”).
CONFIDENTIAL TREATMENT REQUESTED Paid-up License AgreementConfidential Treatment Requested • October 7th, 2014 • Histogenics Corp • Orthopedic, prosthetic & surgical appliances & supplies
THIS AGREEMENT made and entered into as of March 6, 2013 by and between KOKEN Co., Ltd. (hereinafter referred to as “KOKEN”) and HISTOGENICS CORPORATION (hereinafter referred to as “HISTOGENICS”).
SECOND AMENDED AND RESTATED DEVELOPMENT AND COMMERCIALIZATION AGREEMENT between Swedish Orphan Biovitrum AB (publ) and Biogen Idec Hemophilia Inc. CONFIDENTIAL TREATMENT REQUESTED FOIA EXEMPTION CLAIMED AND PRIOR NOTIFICATION REQUESTED BEFORE ANY...Confidential Treatment Requested • December 20th, 2016 • Bioverativ Inc. • Pharmaceutical preparations • New York
THIS SECOND AMENDED AND RESTATED DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (the “Agreement”), dated as of April 10, 2014 (the “Effective Date”) is entered into between Swedish Orphan Biovitrum AB (publ), a Swedish corporation having a place of business at Tomtebodavägen 23A, Solna, Stockholm, SE-112 76, Sweden (“Sobi”) and Biogen Idec Hemophilia Inc., a Delaware corporation having a place of business at 14 Cambridge Center, Cambridge, MA 02142 USA (“Biogen Idec”). Each of Sobi and Biogen Idec shall be referred to herein as a “Party,” and collectively as the “Parties”.
CONFIDENTIAL TREATMENT REQUESTED ASSIGNMENT AND LICENSE AGREEMENTConfidential Treatment Requested • October 23rd, 2017 • Spero Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This ASSIGNMENT AND LICENSE AGREEMENT (this “Agreement”) is entered into as of May 9, 2016 (the “Effective Date”), by and between Vertex Pharmaceuticals Incorporated, with an address at 50 Northern Avenue, Boston, Massachusetts 02210 (“Vertex”) and Spero Trinem, Inc., with an address at 675 Massachusetts Avenue, 14th Floor, Cambridge, Massachusetts 02139 (“Spero”) and solely for the purposes of Section 13.15, Spero Therapeutics, LLC, with an address at 675 Massachusetts Avenue, 14th Floor, Cambridge, Massachusetts 02139 (“Parent”). Vertex and Spero each may be referred to herein individually as a “Party” or collectively as the “Parties.”
CONFIDENTIAL TREATMENT REQUESTED Redacted Portions are indicated by [****] TERM SHEET FOR LICENSE AGREEMENT (Term Sheet)Confidential Treatment Requested • June 25th, 2012 • Atossa Genetics Inc • Surgical & medical instruments & apparatus
The Term Sheet is the initial basis for an offer to license the intellectual property rights specified below, and sets forth the primary licensing terms as agreed upon by the undersigned parties, to be codified in a license agreement which is to be negotiated in full between the parties.
OEM/PLM SUPPLY AGREEMENTConfidential Treatment Requested • July 17th, 2018 • Establishment Labs Holdings Inc. • Orthopedic, prosthetic & surgical appliances & supplies • California
This OEM/PLM and SUPPLY AGREEMENT (“Agreement”) is made by and between, Black Tie Medical, Inc., dba Tulip Medical Products (“TULIP”) and Establishment Labs S.A., a company organized and existing under the laws of Costa Rica (“ELSA”) as of July 31, 2016 (“Effective Date”) pursuant to the following terms, conditions and recitals:
CONFIDENTIAL TREATMENT REQUESTEDConfidential Treatment Requested • May 9th, 2018 • Immunogen Inc • Pharmaceutical preparations • Delaware
This Multi-Target Agreement (this “Agreement”) is made effective as of the date of the last signature below (the “Effective Date”) by and between ImmunoGen, Inc., a Massachusetts corporation (“ImmunoGen”), with its principal place of business at 830 Winter Street, Waltham, Massachusetts 02451, and Eli Lilly and Company, an Indiana corporation (“Lilly”), with its principal place of business at Lilly Corporate Center, Indianapolis, Indiana 46285. ImmunoGen and Lilly are sometimes each hereinafter referred to individually as a “Party” and collectively as the “Parties.”
DEVELOPMENT AND LICENSE AGREEMENTConfidential Treatment Requested • March 30th, 2015 • Pieris Pharmaceuticals, Inc. • Services-commercial physical & biological research • New York
THIS LICENSE AGREEMENT (the “Agreement”) is made and is effective as of this 7th day of October, 2013 (the “Effective Date”) by and between
FIFTY NORTHERN AVENUE LLC AND VERTEX PHARMACEUTICALS INCORPORATED LEASE FOR 50 NORTHERN AVENUE (PARCEL A — FAN PIER) BOSTON, MASSACHUSETTSConfidential Treatment Requested • August 9th, 2011 • Vertex Pharmaceuticals Inc / Ma • Pharmaceutical preparations • Massachusetts
CONFIDENTIAL TREATMENT REQUESTED OPTION AGREEMENTConfidential Treatment Requested • August 12th, 2015 • Mabvax Therapeutics Holdings, Inc. • Pharmaceutical preparations • Delaware
This Option Agreement (the “Agreement”), effective as of August 29, 2014 (the “Effective Date”), is entered by and between MabVax Therapeutics, Inc., with a principal place of business at 11588 Sorrento Valley Road, Suite 20, San Diego, CA 92121 (“MabVax”), and Juno Therapeutics, Inc., with a principal place of business at 307 Westlake Avenue North, Suite 300, Seattle, WA 98109 (“Juno”).
CONFIDENTIAL TREATMENT REQUESTED AMENDMENT AGREEMENT NO. 2 TO THE RESEARCH COLLABORATION AND LICENSE AGREEMENTConfidential Treatment Requested • September 11th, 2014 • Vitae Pharmaceuticals, Inc • Pharmaceutical preparations
This Amendment Agreement No. 2 (“Amendment”) is made to the BACE Research Collaboration and License Agreement between Vitae Pharmaceuticals, Inc. (“Vitae”), with offices at 502 West Office Center Drive, Fort Washington, PA 19034, USA (taxpayer ID number 04-03567753), and Boehringer Ingelheim International GmbH (“BI”), with offices at Binger Strasse 173, 55216 Ingelheim am Rhein, Germany (VAT ID number DE 811138149), effective as of June 4, 2009, as amended in the Amendment No. 1 dated June 7, 2011 (together the “Agreement”).
CONFIDENTIAL TREATMENT REQUESTED [***] – CONFIDENTIAL PORTIONS OF THIS AGREEMENT WHICH HAVE BEEN REDACTED ARE MARKED WITH BRACKETS (“[***]”). THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION....Confidential Treatment Requested • September 19th, 2011 • Bovie Medical Corp • Surgical & medical instruments & apparatus • Delaware
THIS IS AN AGREEMENT between Medtronic, Inc. (“Medtronic”), a Minnesota corporation with its principal place of business at 710 Medtronic Parkway, Minneapolis, Minnesota 55432, Salient Surgical Technologies, Inc. (“Salient”), a Delaware corporation with its principal place of business at 180 International Drive, Portsmouth, New Hampshire 03801, and Bovie Medical Corporation (“Bovie”), a Delaware corporation with its principal place of business at 734 Walt Whitman Road, Melville, New York 11747 (the “Agreement”). Medtronic and Salient are collectively referred to hereinafter as “Plaintiffs”, and Medtronic, Salient, and Bovie are collectively referred to hereinafter as the “Parties”.
CONSULTANT SERVICES AND CONFIDENTIALITY AGREEMENTConfidential Treatment Requested • November 15th, 2006 • Obagi Medical Products, Inc. • Pharmaceutical preparations • Delaware
This Consultant Services and Confidentiality Agreement (the “Agreement”) is made and entered into as of the 18th day of July, 2005 (the “Effective Date”) by and between Obagi Medical Products, Inc., a Delaware corporation (“OMP” or “Company”) and Jose Ramirez and JR Chem LLC (“JR” or “Consultant”).
Exhibit 10.15 THIS AGREEMENT made in duplicate as of this 9th day of August, 2000. BETWEEN:Confidential Treatment Requested • March 29th, 2002 • Boston Life Sciences Inc /De • Pharmaceutical preparations • Ontario
